$436.98
+0.12
(+0.03%)▲
Revenue is up for the last 3 quarters, 828.56M → 943.63M (in $), with an average increase of 6.3% per quarter
Netprofit is up for the last 3 quarters, 172.20M → 224.23M (in $), with an average increase of 12.1% per quarter
0.46%
Downside
Day's Volatility :1.45%
Upside
0.99%
27.44%
Downside
52 Weeks Volatility :43.86%
Upside
22.62%
Period | Idexx Laboratories, Inc. | Sector (Health Care) | Index (NASDAQ Composite) |
---|---|---|---|
3 Months | -11.63% | -1.7% | -3.7% |
6 Months | -10.39% | 1.3% | 9.8% |
1 Year | 31.66% | 5.1% | 21.9% |
3 Years | 13.07% | 24.3% | 18.1% |
Market Capitalization | 35.9B |
Book Value | $13.17 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | 9.34 |
PE Ratio | 46.3 |
PEG Ratio | 7.21 |
Wall Street Target Price | 579.13 |
Profit Margin | 22.52% |
Operating Margin TTM | 29.82% |
Return On Assets TTM | 23.91% |
Return On Equity TTM | 102.06% |
Revenue TTM | 3.5B |
Revenue Per Share TTM | 42.31 |
Quarterly Revenue Growth YOY | 9.700000000000001% |
Gross Profit TTM | 2.0B |
EBITDA | 1.2B |
Diluted Eps TTM | 9.34 |
Quarterly Earnings Growth YOY | 0.71 |
EPS Estimate Current Year | 9.84 |
EPS Estimate Next Year | 11.15 |
EPS Estimate Current Quarter | 2.47 |
EPS Estimate Next Quarter | 2.4 |
What analysts predicted
Upside of 32.53%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 2.0B | ↑ 10.91% |
Net Income | 263.1M | ↑ 18.51% |
Net Profit Margin | 13.36% | ↑ 0.85% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 2.2B | ↑ 12.4% |
Net Income | 377.0M | ↑ 43.28% |
Net Profit Margin | 17.04% | ↑ 3.68% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 2.4B | ↑ 8.75% |
Net Income | 427.7M | ↑ 13.44% |
Net Profit Margin | 17.77% | ↑ 0.73% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 2.7B | ↑ 12.45% |
Net Income | 581.8M | ↑ 36.02% |
Net Profit Margin | 21.49% | ↑ 3.72% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 3.2B | ↑ 18.79% |
Net Income | 744.8M | ↑ 28.03% |
Net Profit Margin | 23.17% | ↑ 1.68% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 3.4B | ↑ 4.73% |
Net Income | 679.1M | ↓ 8.83% |
Net Profit Margin | 20.17% | ↓ 3.0% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 836.5M | ↑ 4.43% |
Net Income | 194.0M | ↑ 19.16% |
Net Profit Margin | 23.19% | ↑ 2.87% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 860.5M | ↑ 2.87% |
Net Income | 132.0M | ↓ 31.96% |
Net Profit Margin | 15.34% | ↓ 7.85% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 841.7M | ↓ 2.19% |
Net Income | 180.9M | ↑ 37.1% |
Net Profit Margin | 21.5% | ↑ 6.16% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 828.6M | ↓ 1.56% |
Net Income | 172.2M | ↓ 4.83% |
Net Profit Margin | 20.78% | ↓ 0.72% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 900.2M | ↑ 8.64% |
Net Income | 214.1M | ↑ 24.3% |
Net Profit Margin | 23.78% | ↑ 3.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 943.6M | ↑ 4.83% |
Net Income | 224.2M | ↑ 4.76% |
Net Profit Margin | 23.76% | ↓ 0.02% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 1.7B | ↑ 11.94% |
Total Liabilities | 1.8B | ↑ 7.83% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.5B | ↓ 10.28% |
Total Liabilities | 1.5B | ↓ 12.49% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.8B | ↑ 19.2% |
Total Liabilities | 1.7B | ↑ 6.99% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 2.3B | ↑ 25.22% |
Total Liabilities | 1.7B | ↑ 0.43% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 2.4B | ↑ 6.22% |
Total Liabilities | 1.7B | ↑ 5.14% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 2.7B | ↑ 12.7% |
Total Liabilities | 2.1B | ↑ 22.37% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.6B | ↑ 6.38% |
Total Liabilities | 2.0B | ↑ 11.77% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.6B | ↑ 0.56% |
Total Liabilities | 2.2B | ↑ 10.1% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.6B | ↑ 1.26% |
Total Liabilities | 2.2B | ↑ 0.65% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.7B | ↑ 4.04% |
Total Liabilities | 2.1B | ↓ 1.2% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.7B | ↓ 39.6% |
Total Liabilities | 2.0B | ↓ 7.99% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.7B | ↑ 1.98% |
Total Liabilities | 1.8B | ↓ 9.68% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 373.3M | ↑ 11.57% |
Investing Cash Flow | -138.7M | ↑ 52.76% |
Financing Cash Flow | -208.0M | ↓ 4.5% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 400.1M | ↑ 7.18% |
Investing Cash Flow | 138.6M | ↓ 199.94% |
Financing Cash Flow | -597.8M | ↑ 187.38% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 459.2M | ↑ 14.77% |
Investing Cash Flow | -205.5M | ↓ 248.29% |
Financing Cash Flow | -286.4M | ↓ 52.09% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 648.1M | ↑ 41.14% |
Investing Cash Flow | -109.4M | ↓ 46.78% |
Financing Cash Flow | -248.4M | ↓ 13.27% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 755.5M | ↑ 16.59% |
Investing Cash Flow | -293.0M | ↑ 167.85% |
Financing Cash Flow | -697.4M | ↑ 180.74% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 114.7M | ↓ 45.37% |
Investing Cash Flow | -41.8M | ↓ 5.0% |
Financing Cash Flow | -13.5M | ↓ 91.87% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 65.9M | ↓ 42.59% |
Investing Cash Flow | -55.1M | ↑ 31.66% |
Financing Cash Flow | -91.9M | ↑ 581.8% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 189.0M | ↑ 187.02% |
Investing Cash Flow | -49.2M | ↓ 10.69% |
Financing Cash Flow | -148.8M | ↑ 61.93% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 183.9M | ↑ 6.05% |
Investing Cash Flow | -39.5M | - |
Financing Cash Flow | -146.1M | ↑ 25.16% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 200.3M | ↑ 8.92% |
Investing Cash Flow | -27.5M | ↓ 30.48% |
Financing Cash Flow | -151.0M | ↑ 3.39% |
Sell
Neutral
Buy
Idexx Laboratories, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Idexx Laboratories, Inc. | -14.57% | -10.39% | 31.66% | 13.07% | 75.5% |
![]() Agilent Technologies Inc. | -7.86% | -16.69% | -9.97% | 10.26% | 55.07% |
![]() Thermo Fisher Scientific, Inc. | -9.43% | -9.39% | -3.77% | 16.32% | 104.15% |
![]() Danaher Corp. | -6.37% | -0.12% | -7.06% | 17.95% | 127.72% |
![]() Iqvia Holdings Inc. | -12.19% | 2.48% | 11.34% | 30.64% | 55.46% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Idexx Laboratories, Inc. | 46.3 | 46.3 | 7.21 | 9.84 | 1.02 | 0.24 | 0.0 | 13.17 |
![]() Agilent Technologies Inc. | 28.99 | 28.99 | 2.36 | 5.42 | 0.21 | 0.09 | 0.01 | 18.99 |
![]() Thermo Fisher Scientific, Inc. | 34.01 | 34.01 | 4.28 | 22.38 | 0.13 | 0.05 | 0.0 | 113.36 |
![]() Danaher Corp. | 29.01 | 29.01 | 3.24 | 8.83 | 0.13 | 0.06 | 0.0 | 70.06 |
![]() Iqvia Holdings Inc. | 34.12 | 34.12 | 1.48 | 10.31 | 0.2 | 0.05 | 0.0 | 31.39 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Idexx Laboratories, Inc. | Buy | $35.9B | 75.5% | 46.3 | 22.52% |
![]() Agilent Technologies Inc. | Buy | $32.4B | 55.07% | 28.99 | 16.2% |
![]() Thermo Fisher Scientific, Inc. | Buy | $192.3B | 104.15% | 34.01 | 13.14% |
![]() Danaher Corp. | Buy | $182.7B | 127.72% | 29.01 | 20.95% |
![]() Iqvia Holdings Inc. | Buy | $36.8B | 55.46% | 34.12 | 7.47% |
BlackRock Inc
Vanguard Group Inc
State Street Corporation
AllianceBernstein L.P.
Fundsmith LLP
BAMCO Inc
idexx laboratories, inc. (nasdaq: idxx) is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. headquartered in southern maine, idexx conducts operations through more than 70 locations around the world, serves customers in over 175 countries, and employs more than 6,000 people. idexx's primary business focuses on pet health, a growing market around the world. idexx products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. idexx also develops and manufactures diagnostic tests and information for the global production animal industry, including poultry and livestock, as well as tests for the quality and safety of water an
Organization | Idexx Laboratories, Inc. |
Employees | 11000 |
CEO | Mr. Jonathan J. Mazelsky |
Industry | Health Technology |
Realty Income Corporation
$436.98
+0.03%
Caterpillar Inc.
$436.98
+0.03%
Sun Communities Inc
$436.98
+0.03%
Liberty Media Group - Class A
$436.98
+0.03%
Fresenius Medical Care Ag & Co. Kgaa
$436.98
+0.03%
Weyerhaeuser Co.
$436.98
+0.03%
Global Payments Inc.
$436.98
+0.03%
Martin Marietta Materials, Inc.
$436.98
+0.03%
Nextera Energy, Inc.
$436.98
+0.03%